GEROPHARM Group participated in the V Annual International Partnering
Forum “Life Sciences Invest. Partnering Russia” which took place on
10-11 November in St. Petersburg.
The event was supported by the Government of St. Petersburg, the
Ministry of Education and Science, the Ministry of Industry and Trade
and the Ministry of Healthcare of the Russian Federation. The forum was
arranged by the non-commercial partnership "Medico-pharmaceutical
projects. 21 century" and St. Petersburg State Chemical-Pharmaceutical
This year the forum’s business and exhibition programmmes gathered
over 300 experts: the representatives of public authorities, research
centres and educational institutions; the heads of manufacturing
companies, the drug and medical devices developers and suppliers and
also the representatives of international and Russian biopharmaceutical
and medical companies.
The experts of GEROPHARM Group were involved in a number of business
programme’s events on the issues concerning legislative regulation of
pharmaceutical activities and drug provision, new medicines circulation
in the Customs Union and staff training system.
The director of economic security of GEROPHARM Group Andrey Akhantev
and the head of government relations unit Vilena Boyko took part in the
roundtable devoted to the problems of industry interaction in the sphere
of pharmaceutical activities and drug provision regulation in Russia
and the Eurasian Economic Space. During the thematic session the latest
changes in the legislative regulation of pharmaceutical activities and
drug provision, quality control and new drugs introduction and
circulation in the Customs Union were discussed. Special attention was
paid to the current situation with the regulatory environment: with the
adoption of the Federal law № 44, for the first time in the modern
history of Russian pharmaceutical market, the local manufacturers gained
an equal access to the government procurement market. However, despite
the positive dynamics, there are still some problems connected with the
imperfection of law-enforcement practice, and, above all, there are
still no real mechanisms aimed to support local manufacturers depending
on the depth of localization.
The 2015 forum gave all the participants a unique chance to discuss
lots of relevant issues on industry development: from regulatory matters
and urgent problems connected with the production and scientific bases
development to the questions concerning human resourcing. The 70-year
anniversary of St. Petersburg State Chemical-Pharmaceutical Academy’s
faculty of drug industrial technology provided a great opportunity to
turn to a number of issues in this regard. The HR director of GEROPHARM
Group Natalya Skakunova participated in the faculty congratulation
ceremony. As the expert of the session devoted to the problems of staff
system building and development in the pharmaceutical field she also
made a short presentation. Today it is very important to think of the
students’ competences which can be developed during their professional
education in the sphere of pharmaceutics. Besides professional
knowledge, it is also crucial to guide young specialists towards the
appropriate work approaches that today, besides professional knowledge
and skills, also require information handling, responsibility, result
orientation, strong communication skills and ability to follow corporate
culture. All experts noted the importance of early career guidance.
Anyway, all proactive pharmaceutical companies have already been engaged
in working not only with students but also with pupils. Some specific
proposals on methods of combining efforts in this regard at business and
city administration levels were offered.
The anniversary partnering forum also impressed visitors with a small exposition, where the company presented its original drugs Cortexin®, Retinalamin®, generics Levetinol®, Memantinol® and genetically engineered human insulins Rinsulin® R (short-acting) and Rinsulin® NPH (average duration) in different delivery forms (vials, cartridges, pre-filled insulin pens). The stand reflected not only the company’s successful projects focused on import substitution but also serious competences of the leading Russian pharmaceutical manufacturer in the sphere of original drugs, biotechnological products and improved generic drugs development and manufacturing.